These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area. Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298 [TBL] [Abstract][Full Text] [Related]
23. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431 [TBL] [Abstract][Full Text] [Related]
24. BRAF Kaabouch M; Chahdi H; Azouzi N; Oukabli M; Rharrassi I; Boudhas A; Jaddi H; Ababou M; Dakka N; Boichard A; Bakri Y; Dupuy C; Al Bouzidi A; El Hassani RA Afr Health Sci; 2020 Dec; 20(4):1849-1856. PubMed ID: 34394248 [TBL] [Abstract][Full Text] [Related]
25. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237 [TBL] [Abstract][Full Text] [Related]
26. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058 [TBL] [Abstract][Full Text] [Related]
28. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937 [TBL] [Abstract][Full Text] [Related]
29. Loss of heterozygosity of the long arm of chromosome 7 in follicular and anaplastic thyroid cancer, but not in papillary thyroid cancer. Trovato M; Fraggetta F; Villari D; Batolo D; Mackey K; Trimarchi F; Benvenga S J Clin Endocrinol Metab; 1999 Sep; 84(9):3235-40. PubMed ID: 10487693 [TBL] [Abstract][Full Text] [Related]
30. Papillary thyroid cancer organoids harboring BRAF Chen D; Su X; Zhu L; Jia H; Han B; Chen H; Liang Q; Hu C; Yang H; Liu L; Li P; Wei W; Zhao Y J Transl Med; 2023 Jan; 21(1):9. PubMed ID: 36624452 [TBL] [Abstract][Full Text] [Related]
31. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549 [TBL] [Abstract][Full Text] [Related]
32. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Begum S; Rosenbaum E; Henrique R; Cohen Y; Sidransky D; Westra WH Mod Pathol; 2004 Nov; 17(11):1359-63. PubMed ID: 15195111 [TBL] [Abstract][Full Text] [Related]
33. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932 [TBL] [Abstract][Full Text] [Related]
34. Sorafenib in Metastatic Papillary Thyroid Carcinoma with Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083 [TBL] [Abstract][Full Text] [Related]
35. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400 [TBL] [Abstract][Full Text] [Related]
36. Synergistic Anticancer Activity of Yun HJ; Kim HJ; Kim J; Kim SY; Chang HS; Park CS; Chang HJ; Park KC Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430361 [TBL] [Abstract][Full Text] [Related]
37. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma. Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921 [TBL] [Abstract][Full Text] [Related]
38. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777 [TBL] [Abstract][Full Text] [Related]
39. Novel treatments for anaplastic thyroid carcinoma. Ferrari SM; Elia G; Ragusa F; Ruffilli I; La Motta C; Paparo SR; Patrizio A; Vita R; Benvenga S; Materazzi G; Fallahi P; Antonelli A Gland Surg; 2020 Jan; 9(Suppl 1):S28-S42. PubMed ID: 32055496 [TBL] [Abstract][Full Text] [Related]